University of Hertfordshire

Standard

Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium. / Gorog, Diana A.; Storey, Robert F.; Gurbel, Paul A.; Tantry, Udaya S.; Berger, Jeffrey S.; Chan, Mark Y.; Duerschmied, Daniel; Smyth, Susan S.; Parker, William A.E.; Ajjan, Ramzi A.; Vilahur, Gemma; Badimon, Lina; Berg, Jurrien M.ten; Cate, Hugo ten; Peyvandi, Flora; Wang, Taia T.; Becker, Richard C.

In: Nature Reviews Cardiology, 13.01.2022.

Research output: Contribution to journalReview articlepeer-review

Harvard

Gorog, DA, Storey, RF, Gurbel, PA, Tantry, US, Berger, JS, Chan, MY, Duerschmied, D, Smyth, SS, Parker, WAE, Ajjan, RA, Vilahur, G, Badimon, L, Berg, JMT, Cate, HT, Peyvandi, F, Wang, TT & Becker, RC 2022, 'Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium', Nature Reviews Cardiology. https://doi.org/10.1038/s41569-021-00665-7

APA

Gorog, D. A., Storey, R. F., Gurbel, P. A., Tantry, U. S., Berger, J. S., Chan, M. Y., Duerschmied, D., Smyth, S. S., Parker, W. A. E., Ajjan, R. A., Vilahur, G., Badimon, L., Berg, J. M. T., Cate, H. T., Peyvandi, F., Wang, T. T., & Becker, R. C. (2022). Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium. Nature Reviews Cardiology. https://doi.org/10.1038/s41569-021-00665-7

Vancouver

Author

Gorog, Diana A. ; Storey, Robert F. ; Gurbel, Paul A. ; Tantry, Udaya S. ; Berger, Jeffrey S. ; Chan, Mark Y. ; Duerschmied, Daniel ; Smyth, Susan S. ; Parker, William A.E. ; Ajjan, Ramzi A. ; Vilahur, Gemma ; Badimon, Lina ; Berg, Jurrien M.ten ; Cate, Hugo ten ; Peyvandi, Flora ; Wang, Taia T. ; Becker, Richard C. / Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium. In: Nature Reviews Cardiology. 2022.

Bibtex

@article{ee93a2680f4847248dfdc3394d15aaff,
title = "Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium",
abstract = "Coronavirus disease 2019 (COVID-19) predisposes patients to thrombotic and thromboembolic events, owing to excessive inflammation, endothelial cell activation and injury, platelet activation and hypercoagulability. Patients with COVID-19 have a prothrombotic or thrombophilic state, with elevations in the levels of several biomarkers of thrombosis, which are associated with disease severity and prognosis. Although some biomarkers of COVID-19-associated coagulopathy, including high levels of fibrinogen and d-dimer, were recognized early during the pandemic, many new biomarkers of thrombotic risk in COVID-19 have emerged. In this Consensus Statement, we delineate the thrombotic signature of COVID-19 and present the latest biomarkers and platforms to assess the risk of thrombosis in these patients, including markers of platelet activation, platelet aggregation, endothelial cell activation or injury, coagulation and fibrinolysis as well as biomarkers of the newly recognized post-vaccine thrombosis with thrombocytopenia syndrome. We then make consensus recommendations for the clinical use of these biomarkers to inform prognosis, assess disease acuity, and predict thrombotic risk and in-hospital mortality. A thorough understanding of these biomarkers might aid risk stratification and prognostication, guide interventions and provide a platform for future research.",
author = "Gorog, {Diana A.} and Storey, {Robert F.} and Gurbel, {Paul A.} and Tantry, {Udaya S.} and Berger, {Jeffrey S.} and Chan, {Mark Y.} and Daniel Duerschmied and Smyth, {Susan S.} and Parker, {William A.E.} and Ajjan, {Ramzi A.} and Gemma Vilahur and Lina Badimon and Berg, {Jurrien M.ten} and Cate, {Hugo ten} and Flora Peyvandi and Wang, {Taia T.} and Becker, {Richard C.}",
note = "{\textcopyright} Springer Nature Limited 2022. This is the accepted manuscript version of an article which has been published in final form at https://doi.org/10.1038/s41569-021-00665-7",
year = "2022",
month = jan,
day = "13",
doi = "10.1038/s41569-021-00665-7",
language = "English",
journal = "Nature Reviews Cardiology",
issn = "1759-5002",
publisher = "Nature Publishing Group",

}

RIS

TY - JOUR

T1 - Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium

AU - Gorog, Diana A.

AU - Storey, Robert F.

AU - Gurbel, Paul A.

AU - Tantry, Udaya S.

AU - Berger, Jeffrey S.

AU - Chan, Mark Y.

AU - Duerschmied, Daniel

AU - Smyth, Susan S.

AU - Parker, William A.E.

AU - Ajjan, Ramzi A.

AU - Vilahur, Gemma

AU - Badimon, Lina

AU - Berg, Jurrien M.ten

AU - Cate, Hugo ten

AU - Peyvandi, Flora

AU - Wang, Taia T.

AU - Becker, Richard C.

N1 - © Springer Nature Limited 2022. This is the accepted manuscript version of an article which has been published in final form at https://doi.org/10.1038/s41569-021-00665-7

PY - 2022/1/13

Y1 - 2022/1/13

N2 - Coronavirus disease 2019 (COVID-19) predisposes patients to thrombotic and thromboembolic events, owing to excessive inflammation, endothelial cell activation and injury, platelet activation and hypercoagulability. Patients with COVID-19 have a prothrombotic or thrombophilic state, with elevations in the levels of several biomarkers of thrombosis, which are associated with disease severity and prognosis. Although some biomarkers of COVID-19-associated coagulopathy, including high levels of fibrinogen and d-dimer, were recognized early during the pandemic, many new biomarkers of thrombotic risk in COVID-19 have emerged. In this Consensus Statement, we delineate the thrombotic signature of COVID-19 and present the latest biomarkers and platforms to assess the risk of thrombosis in these patients, including markers of platelet activation, platelet aggregation, endothelial cell activation or injury, coagulation and fibrinolysis as well as biomarkers of the newly recognized post-vaccine thrombosis with thrombocytopenia syndrome. We then make consensus recommendations for the clinical use of these biomarkers to inform prognosis, assess disease acuity, and predict thrombotic risk and in-hospital mortality. A thorough understanding of these biomarkers might aid risk stratification and prognostication, guide interventions and provide a platform for future research.

AB - Coronavirus disease 2019 (COVID-19) predisposes patients to thrombotic and thromboembolic events, owing to excessive inflammation, endothelial cell activation and injury, platelet activation and hypercoagulability. Patients with COVID-19 have a prothrombotic or thrombophilic state, with elevations in the levels of several biomarkers of thrombosis, which are associated with disease severity and prognosis. Although some biomarkers of COVID-19-associated coagulopathy, including high levels of fibrinogen and d-dimer, were recognized early during the pandemic, many new biomarkers of thrombotic risk in COVID-19 have emerged. In this Consensus Statement, we delineate the thrombotic signature of COVID-19 and present the latest biomarkers and platforms to assess the risk of thrombosis in these patients, including markers of platelet activation, platelet aggregation, endothelial cell activation or injury, coagulation and fibrinolysis as well as biomarkers of the newly recognized post-vaccine thrombosis with thrombocytopenia syndrome. We then make consensus recommendations for the clinical use of these biomarkers to inform prognosis, assess disease acuity, and predict thrombotic risk and in-hospital mortality. A thorough understanding of these biomarkers might aid risk stratification and prognostication, guide interventions and provide a platform for future research.

UR - http://www.scopus.com/inward/record.url?scp=85122966329&partnerID=8YFLogxK

U2 - 10.1038/s41569-021-00665-7

DO - 10.1038/s41569-021-00665-7

M3 - Review article

AN - SCOPUS:85122966329

JO - Nature Reviews Cardiology

JF - Nature Reviews Cardiology

SN - 1759-5002

ER -